SPH3127 (DRI 18) is a novel, highly potent, and orally active direct renin inhibitor (recombinant human-renin IC 50 =0.4 nM, human plasma renin activity IC 50 =0.45 nM). SPH3127 shows antihypertensive effect and can be used in essential hypertension research.In VivoSPH3127 (oral administration; 0-10 mg/kg; once) shows favorable bioavailability in cynomolgus monkeys . SPH3127 (oral administration; 0-3 mg/kg; once) shows a hypotensive effect on tsukuba hypertensive mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Cynomolgus monkeys pretreated with a low-sodium diet and furosemide Dosage: 0, 1, 3, and 10 mg/kg Administration: Oral administration; 1, 3, and 10 mg/kg; once Result: Inhibited plasma renin activity with the IC 50 value of 0.46 nM, and showed hypotensive effect. Animal Model: Tsukuba hypertensive mice (THM) Dosage: 0, 0.3, 1, or 3 mg/kg Administration: Oral administration; 0, 0.3, 1, or 3 mg/kg; once Result: Exhibited a hypotensive effect on tsukuba hypertensive mice in a dose-dependent manner from 0.3 to 3 mg/kg, and showed a maximum hypotensive effect of approximately 30 mmHg at 2-3 h after administration at any dose.Form:Solid. Specification: 0.98 Molecular Formula: C22H32N6O4 Molecular Weight: 444.53 PubChem CID: 117877477 Isomeric SMILES: CC1=NC2=C(C=C1)C(=NN2CCCNC(=O)OC)[C@@H](C)N(C3CC3)C(=O)[C@H]4CNCCO4
- UPC:
- 51433104
- Condition:
- New
- Availability:
- 8-12 weeks
- Weight:
- 1.06 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- S651760-10mg
- CAS:
- 1399849-02-5
- Product Size:
- 10mg
